{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:38:03Z","timestamp":1790660283360,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1097\/tp.0000000000004696","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:02:02Z","timestamp":1686873722000},"page":"593-597","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Acute Rejection After Kidney Transplant\u2014An Endpoint Not Predictive of Treatment Effect on Graft Survival"],"prefix":"10.1097","volume":"108","author":[{"given":"William E.","family":"Fitzsimmons","sequence":"first","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois, Chicago, IL."},{"name":"Department of Physiology and Biophysics, College of Medicine, University of Illinois at Chicago, Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Naesens","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium."},{"name":"Department of Nephrology, UZ Leuven, Leuven, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation.","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"issue":"suppl 3","key":"R4-20250604","article-title":"Renal function at five years from a randomized multicenter trial of belatacept-based CNI free and early steroid withdrawal immunosuppression. [abstract].","volume":"22","author":"Yanqui","year":"2022","journal-title":"Am J Transplant"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/SLA.0b013e318187d1da","article-title":"A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.","volume":"248","author":"Woodle","year":"2008","journal-title":"Ann Surg"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation.","volume":"364","author":"Hanaway","year":"2011","journal-title":"N Engl J Med"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/ajt.13191","article-title":"Daclizumab versus rabbit antithymocyte globulin in high-risk renal transplants: five-year follow-up of a randomized study.","volume":"15","author":"Hellemans","year":"2015","journal-title":"Am J Transplant"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/00007890-200203150-00021","article-title":"A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years.","volume":"73","author":"Vincenti","year":"2002","journal-title":"Transplantation"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/00007890-199704150-00013","article-title":"A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.","volume":"63","author":"Pirsch","year":"1997","journal-title":"Transplantation"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.trim.2008.08.005","article-title":"Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.","volume":"20","author":"Anil Kumar","year":"2008","journal-title":"Transpl Immunol"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000085892","article-title":"Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study.","volume":"25","author":"Sheashaa","year":"2005","journal-title":"Am J Nephrol"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/TP.0b013e318187bc67","article-title":"A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results.","volume":"86","author":"Hardinger","year":"2008","journal-title":"Transplantation"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/ajt.15591","article-title":"Efficacy and safety of bleselumab in kidney transplant recipients: a phase 2, randomized, open-label, noninferiority study.","volume":"20","author":"Harland","year":"2020","journal-title":"Am J Transplant"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ajt.12952","article-title":"Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.","volume":"15","author":"Budde","year":"2015","journal-title":"Am J Transplant"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1600-6143.2009.02726.x","article-title":"Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.","volume":"9","author":"Ekberg","year":"2009","journal-title":"Am J Transplant"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","article-title":"Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients.","volume":"60","author":"Sollinger","year":"1995","journal-title":"Transplantation"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0272-6386(99)70358-6","article-title":"Mycophenolate mofetil in cadaveric renal transplantation.","volume":"34","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/00007890-199806150-00007","article-title":"A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.","volume":"65","author":"Mathew","year":"1998","journal-title":"Transplantation"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00007890-199908150-00011","article-title":"Mycophenolate mofetil in renal transplantation:3-year results from the placebo-controlled trial.","volume":"68","year":"1999","journal-title":"Transplantation"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(95)92534-1","article-title":"Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection.","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1600-6143.2007.01661.x","article-title":"One-year results with extended-release tacrolimus\/MMF, tacrolimus\/MMF and cyclosporine\/MMF in de novo kidney transplant recipients.","volume":"7","author":"Silva","year":"2007","journal-title":"Am J Transplant"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/01.TP.0000437669.93963.8E","article-title":"Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release\/MMF, tacrolimus\/MMF, and cyclosporine\/MMF in de novo kidney transplant recipients.","volume":"97","author":"Silva","year":"2014","journal-title":"Transplantation"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00007890-200109150-00017","article-title":"Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.","volume":"72","author":"Bumgardner","year":"2001","journal-title":"Transplantation"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","article-title":"A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.","volume":"71","author":"MacDonald","year":"2001","journal-title":"Transplantation"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"10137","DOI":"10.3389\/ti.2022.10137","article-title":"Rationale for surrogate endpoints and conditional marketing authorization of new therapies for kidney transplantation.","volume":"35","author":"Naesens","year":"2022","journal-title":"Transpl Int"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:04:52Z","timestamp":1749045892000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004696","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,16]]}}}